Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

HDAC inhibitor developer Acetylon raises $12.4mm in Series B round; closes at $28mm

Executive Summary

Acetylon Pharmaceuticals Inc. (targeting class II-selective histone deacetylases for the treatment of cancer, inflammation, neurodegeneration, genetic protein disorders, and infectious diseases) has raised $12.4mm towards a Series B financing that could total as much as $30mm according to the Form D filing. A group of 23 backers participated.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies